IDEAS home Printed from https://ideas.repec.org/a/bla/ajecsc/v81y2022i4p721-751.html
   My bibliography  Save this article

When Will the FDA Do What Is in People’s Best Interests?

Author

Listed:
  • Alfred B. Ordman

Abstract

The national effort to reduce the incidence and severity of cancer and other chronic diseases in the United States has suffered from political influences that undermine the interests of the public. As one example, the medical profession has not made adequate use of nutritional information to improve the health of the population. Daily values for vitamins were established in the United States during World War II, when the goal was to avoid short‐term deficiencies so soldiers could continue to fight. But there is more to health than short‐term survival. Linus Pauling advocated megadoses of vitamin C to reduce the risk of cancer and to improve long‐term health. Despite numerous studies demonstrating that better nutrition and exercise are vital to a longer span of good health, the U.S. Food and Drug Administration (FDA) does not permit claims to be made about the health benefits of specific nutritional supplements. The FDA is responsive to political pressures, including pressures to reduce public knowledge of supplements and their benefits. Pharmaceutical companies contribute to members of Congress to influence health policy. Those companies promote legislation and regulations that favor the use of expensive medical treatments and that limit the provision of cost‐effective public health measures. This article reviews many examples of failures of our current medical system, and methods that could prevent the current expense and suffering in this nation.

Suggested Citation

  • Alfred B. Ordman, 2022. "When Will the FDA Do What Is in People’s Best Interests?," American Journal of Economics and Sociology, Wiley Blackwell, vol. 81(4), pages 721-751, September.
  • Handle: RePEc:bla:ajecsc:v:81:y:2022:i:4:p:721-751
    DOI: 10.1111/ajes.12481
    as

    Download full text from publisher

    File URL: https://doi.org/10.1111/ajes.12481
    Download Restriction: no

    File URL: https://libkey.io/10.1111/ajes.12481?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. DiMasi, Joseph A. & Grabowski, Henry G. & Hansen, Ronald W., 2016. "Innovation in the pharmaceutical industry: New estimates of R&D costs," Journal of Health Economics, Elsevier, vol. 47(C), pages 20-33.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Dosis, Anastasios & Muthoo, Abhinay, 2019. "Experimentation in Dynamic R&D Competition," CRETA Online Discussion Paper Series 52, Centre for Research in Economic Theory and its Applications CRETA.
    2. Yusuke Oh & Koji Takahashi, 2020. "R&D and Innovation: Evidence from Patent Data," Bank of Japan Working Paper Series 20-E-7, Bank of Japan.
    3. Gamba, Simona & Magazzini, Laura & Pertile, Paolo, 2021. "R&D and market size: Who benefits from orphan drug legislation?," Journal of Health Economics, Elsevier, vol. 80(C).
    4. Branstetter, Lee & Chatterjee, Chirantan & Higgins, Matthew J., 2022. "Generic competition and the incentives for early-stage pharmaceutical innovation," Research Policy, Elsevier, vol. 51(10).
    5. Sam Peltzman, 2022. "“The theory of economic regulation” after 50 years," Public Choice, Springer, vol. 193(1), pages 7-21, October.
    6. Pierre Dubois & Ashvin Gandhi & Shoshana Vasserman, 2022. "Bargaining and International Reference Pricing in the Pharmaceutical Industry," NBER Working Papers 30053, National Bureau of Economic Research, Inc.
    7. Edouard Debonneuil & Anne Eyraud-Loisel & Frédéric Planchet, 2018. "Can Pension Funds Partially Manage Longevity Risk by Investing in a Longevity Megafund?," Risks, MDPI, vol. 6(3), pages 1-27, July.
    8. Thakur-Wernz, Pooja & Bruyaka, Olga & Contractor, Farok, 2020. "Antecedents and relative performance of sourcing choices for new product development projects," Technovation, Elsevier, vol. 90.
    9. Billette de Villemeur, Etienne & Versaevel, Bruno, 2019. "One lab, two firms, many possibilities: On R&D outsourcing in the biopharmaceutical industry," Journal of Health Economics, Elsevier, vol. 65(C), pages 260-283.
    10. Joshua Krieger & Danielle Li & Dimitris Papanikolaou, 2022. "Missing Novelty in Drug Development," The Review of Financial Studies, Society for Financial Studies, vol. 35(2), pages 636-679.
    11. Fabian Gaessler & Stefan Wagner, 2022. "Patents, Data Exclusivity, and the Development of New Drugs," The Review of Economics and Statistics, MIT Press, vol. 104(3), pages 571-586, May.
    12. Vincenzo Atella & Joanna Kopinska, 2018. "New Technologies and Costs," CEIS Research Paper 442, Tor Vergata University, CEIS, revised 09 Aug 2018.
    13. Hassan Heidari & Arash Refah Kahriz & Yousef Mohammadzadeh, 2019. "Stock market behavior of pharmaceutical industry in Iran and macroeconomic factors," Economic Change and Restructuring, Springer, vol. 52(3), pages 255-277, August.
    14. Gregor Dorfleitner & Felix Rößle, 2018. "The financial performance of the health care industry: a global, regional and industry specific empirical investigation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(4), pages 585-594, May.
    15. Jorge Vieira & Rui Frade & Raquel Ascenso & Filipa Martinho & Domingos Martinho, 2021. "Determinants of Internationalization as Levers for Sustainability: A Study of the Portuguese Pharmaceutical Sector," Sustainability, MDPI, vol. 13(17), pages 1-16, August.
    16. Farasat A. S. Bokhari & Franco Mariuzzo & Anna Rita Bennato, 2021. "Innovation and growth in the UK pharmaceuticals: the case of product and marketing introductions," Small Business Economics, Springer, vol. 57(1), pages 603-634, June.
    17. Stig Johan Wiklund, 2019. "A modelling framework for improved design and decision-making in drug development," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-22, August.
    18. Yin, Nina, 2023. "Pharmaceuticals, incremental innovation and market exclusivity," International Journal of Industrial Organization, Elsevier, vol. 87(C).
    19. Aysun, Uluc, 2020. "Volatility costs of R&D," European Economic Review, Elsevier, vol. 122(C).
    20. Heyoung Yang & Hyuck Jai Lee, 2018. "Long-Term Collaboration Network Based on ClinicalTrials.gov Database in the Pharmaceutical Industry," Sustainability, MDPI, vol. 10(2), pages 1-14, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:bla:ajecsc:v:81:y:2022:i:4:p:721-751. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Wiley Content Delivery (email available below). General contact details of provider: http://www.blackwellpublishing.com/journal.asp?ref=0002-9246 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.